Markets:

Overview

News

Currencies

International

Treasuries

Prometheus Biosciences, Inc. - Common Stock (NQ:RXDX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 15, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Prometheus Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Why Shares of Exscientia Jumped on Wednesday ↗

July 12, 2023

The company may be riding the wave of an AI healthcare boom.

Via The Motley Fool

From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs ↗

July 07, 2023

Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as...

Via Benzinga

Why Shares of Ventyx Biosciences Rose Monday ↗

July 03, 2023

The company has several promising autoimmune therapies.

Via The Motley Fool

Is Merck Stock a Top Buy Right Now? ↗

June 19, 2023

The drugmaker is still a work in progress.

Via The Motley Fool

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

3 Innovative Growth Stocks to Buy for Next-Gen Profits ↗

May 31, 2023

These are the innovative growth stocks for future profits as they represent companies investing significantly in research and development.

Via InvestorPlace

RXDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Prometheus Biosciences, Inc. Is Fair to Shareholders

May 24, 2023

From Halper Sadeh LLC

Via Business Wire

PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX

May 22, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

3 Undervalued Pharma Stocks to Buy for High Total Returns ↗

May 19, 2023

These are the undervalued pharma stocks to buy as they represent companies investing heavily in research to boost the product pipeline.

Via InvestorPlace

FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A ↗

May 16, 2023

In a rare move to block a large pharma deal, the U.S.

Via Benzinga

Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover ↗

May 16, 2023

Reports the FTC could block Amgen's takeover of Horizon reverberated across biotechs on Tuesday, with HZNP stock's crash leading the way.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023 ↗

May 10, 2023

Via Benzinga

Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

May 09, 2023

- Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 -

From Prometheus Biosciences

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX)

May 03, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)

May 01, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Here Are The Best-Performing Industry ETFs And Major Stock Contributors In April ↗

April 30, 2023

It's a good time to look at how the major U.S. stock industry ETFs performed this month, as April comes to an end. In April, we saw the broader U.S.

Via Benzinga

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks? ↗

April 28, 2023

Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.

Via Investor's Business Daily

Merck Makes a Bold Move That Could Transform Its Business ↗

April 27, 2023

It's a risky deal for Merck, but it could pay off significantly.

Via The Motley Fool

3 Biotechs That Might Get Bought Out in 2023 ↗

April 26, 2023

Biotech is expected to be a hotbed of mergers and acquisitions this year.

Via The Motley Fool

April 25, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

This Supercharged Dividend King Stock Might Soon Run Out of Steam ↗

April 25, 2023

Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.

Via The Motley Fool

PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX

April 21, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Stock Market Rally Drifts Lower; Tesla Dives On Margins; ISRG, DHI, LVS Are Winners: Weekly Review ↗

April 21, 2023

The major indexes saw modest declines, holding in a range.

Via Investor's Business Daily

Why Prometheus Biosciences Stock Is Skyrocketing This Week ↗

April 20, 2023

There's nothing like a big buyout to send a clinical-stage biotech stock soaring higher.

Via The Motley Fool

Why This Nasdaq Stock Caught Fire This Week ↗

April 20, 2023

A wave of bargain buying benefited the gene therapy company's shares this week.

Via The Motley Fool

Why Madrigal Pharmaceuticals Stock Gained 20% This Week ↗

April 20, 2023

Two key tailwinds fueled a surge in the biotech's share price this week.

Via The Motley Fool

Is Merck Stock a Screaming Buy After This $11 Billion Acquisition? ↗

April 19, 2023

Merck's move into immunology is a risky proposition.

Via The Motley Fool

Why BELLUS Health Stock Is Rocketing Higher Today ↗

April 18, 2023

A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today.

Via The Motley Fool

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)

April 18, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023 ↗

April 18, 2023

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.